Table 1 |
||
|
Clinicopathological parameters for the clinical tumour set |
||
| Number |
Percentage |
|
|
|
||
| Tumour grade |
||
| Grade 1 |
2 |
2.6 |
| Grade 2 |
29 |
37.7 |
| Grade 3 |
43 |
55.8 |
| Not known |
3 |
3.9 |
| Oestrogen receptor status |
||
| Positive |
46 |
59.7 |
| Negative |
31 |
40.3 |
| Epidermal growth factor receptor (membrane) status |
||
| Positive |
43 |
55.8 |
| Negative |
31 |
40.3 |
| Not known |
3 |
3.9 |
| erbB2 (membrane) status |
||
| Positive |
19 |
71.4 |
| Negative |
55 |
24.7 |
| Not known |
3 |
3.9 |
| erbB3 (membrane) status |
||
| Positive |
61 |
79.3 |
| Negative |
9 |
11.7 |
| Not known |
7 |
9.1 |
| Menopausal status |
||
| Premenopausal |
23 |
31.1 |
| Postmenopausal |
51 |
68.9 |
| Not known |
3 |
3.9 |
| Site of disease |
||
| Locally advanced |
29 |
39.2 |
| Metastatic |
45 |
60.8 |
| Not known |
3 |
3.9 |
| Ki-67 index |
||
| 0 |
10 |
13 |
| <10 |
15 |
19.5 |
| 10–30 |
52 |
67.5 |
|
|
||
|
Hutcheson et al. Breast Cancer Research 2007 9:R50 doi:10.1186/bcr1754 |
||
